

RECORDATI: 2022 CORPORATE EVENTS' CALENDAR

Milan, 11th October 2022 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2022:

24th February	Board of Directors' meeting to approve the 2021 preliminary consolidated results.
17th March	Board of Directors' meeting to approve the 2021 consolidated financial statements and the draft of Recordati S.p.A.'s 2021 financial statements as well as the 2021 consolidated non-financial statement.
29th April	Annual Shareholders' Meeting to approve Recordati S.p.A.'s 2021 financial statements.
10th May	Board of Directors' meeting to approve the 2022 first quarter results.
28th July	Board of Directors' meeting to approve the 2022 half-yearly report.
8th November	Board of Directors' meeting to approve the 2022 first nine months' results.

Recordati S.p.A. announces that the payment of the balance of the 2021 financial year dividend is planned for May 2022, while payment of the interim dividend for the 2022 financial year is planned for November 2022.

Information on payment date, ex-dividend date and record date will be provided after the disclosure of the 2022 trading Calendar of Borsa Italiana.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

***Recordati**, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.*

For further information:

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1
20148 Milano, Italy
Ph. (39) 02 487871
Fax (39) 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l



Recordati website: www.recordati.com

Investor Relations

Federica De Medici

(39) 02 48787146

e-mail: investorelations@recordati.it

Media Relations

Brunswick - Barbara Scalchi / Andrea Mormandi

(39) 02 9288 6200

e-mail: recordati@brunswickgroup.com